Showing results (421-430 of 470) with videos related to
Sort By:
Pageof 47
Breast Cancer Research and Treatment|November 8, 2017
Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancerMothaffar F Rimawi, Carmine De Angelis, Alejandro Contreras, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 20, 2022
The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast CancerCynthia X Ma, Jingqin Luo, Rachel A Freedman, et al.European Journal of Cancer (Oxford, England : 1990)|March 16, 2020
Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiativeRomain Cohen, Dewi Vernerey, Carine Bellera, et al.Cancers|August 26, 2023
Evaluation of Intratumoral Response Heterogeneity in Metastatic Colorectal Cancer and Its Impact on Patient Overall Survival: Findings from 10,551 Patients in the ARCAD DatabaseFang-Shu Ou, Daniel H Ahn, Jesse G Dixon, et al.The New England Journal of Medicine|October 1, 2019
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal CancerScott Kopetz, Axel Grothey, Rona Yaeger, et al.European Journal of Cancer (Oxford, England : 1990)|June 19, 2024
Prognostic value of liver metastases in colorectal cancer treated by systemic therapy: An ARCAD pooled analysisRomain Cohen, Morteza Raeisi, Benoist Chibaudel, et al.The Journal of Clinical Investigation|June 8, 2021
FOXA1 overexpression suppresses interferon signaling and immune response in cancerYundong He, Liguo Wang, Ting Wei, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 4, 2020
Evaluation of Germline Genetic Testing Criteria in a Hospital-Based Series of Women With Breast CancerSiddhartha Yadav, Chunling Hu, Steven N Hart, et al.Nature Communications|April 18, 2023
Distinct spatial immune microlandscapes are independently associated with outcomes in triple-negative breast cancerJodi M Carter, Saranya Chumsri, Douglas A Hinerfeld, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 31, 2017
First-in-Human Phase I Study of the Tamoxifen Metabolite Z-Endoxifen in Women With Endocrine-Refractory Metastatic Breast CancerMatthew P Goetz, Vera J Suman, Joel M Reid, et al.Pageof 47